On Friday, February 16, 2024, Dr. Pasi A. Jänne, MD, PhD, Director of the Lowe Center for Thoracic Oncology and Professor of Medicine, Harvard Medical School; David M. Livingston, MD, Chair at Dana-Farber Cancer Institute, presented the Paul Calabresi, MD, Memorial Lectureship, hosted by Dr. Roy Herbst, Deputy Director of Yale Cancer Center and Smilow Cancer Hospital. A dinner was held in his honor on February 15th, along with a ceremony in the Calabresi Conference Room at Yale Cancer Center. Yale Medical Oncology-Hematology Fellows also had a chance to speak with Dr. Jänne following his talk.
The Paul Calabresi, MD, Memorial Lectureship began in 2006 to honor Yale’s first chief of medical oncology who is often regarded as ‘a statesman of oncology.’ Dr. Calabresi was an internationally-recognized authority and pioneer on the clinical pharmacology of anti-cancer agents, and was an early supporter of combination chemotherapy as well as combined modality therapy, intertwining surgery and radiation therapy with chemotherapy in a safe and effective fashion.
Dr. Jänne's main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer. His clinical interests include epidermal growth factor receptor targeted therapies for lung cancer.